Neurogene (NASDAQ:NGNE – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.
Earnings & Valuation
This table compares Neurogene and Foghorn Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neurogene | $930,000.00 | 507.03 | -$90.35 million | ($5.03) | -4.68 |
| Foghorn Therapeutics | $30.91 million | 3.84 | -$74.28 million | ($0.98) | -2.04 |
Foghorn Therapeutics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Neurogene and Foghorn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neurogene | N/A | -45.10% | -41.00% |
| Foghorn Therapeutics | -175.78% | N/A | -31.17% |
Risk & Volatility
Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500.
Insider and Institutional Ownership
52.4% of Neurogene shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Neurogene and Foghorn Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neurogene | 1 | 0 | 5 | 2 | 3.00 |
| Foghorn Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
Neurogene currently has a consensus target price of $80.29, indicating a potential upside of 240.70%. Foghorn Therapeutics has a consensus target price of $6.14, indicating a potential upside of 207.30%. Given Neurogene’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurogene is more favorable than Foghorn Therapeutics.
Summary
Foghorn Therapeutics beats Neurogene on 8 of the 15 factors compared between the two stocks.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
